These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30969326)

  • 1. Diagnosis and Management of Crohn Disease.
    Feld L; Glick LR; Cifu AS
    JAMA; 2019 May; 321(18):1822-1823. PubMed ID: 30969326
    [No Abstract]   [Full Text] [Related]  

  • 2. Ulcerative Colitis in Adults.
    Glick LR; Cifu AS; Feld L
    JAMA; 2020 Sep; 324(12):1205-1206. PubMed ID: 32857108
    [No Abstract]   [Full Text] [Related]  

  • 3. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors.
    Papi C; Fascì-Spurio F; Rogai F; Settesoldi A; Margagnoni G; Annese V
    Dig Liver Dis; 2013 Dec; 45(12):978-85. PubMed ID: 24018244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bugs and drugs: Predicting response to therapy.
    Ananthakrishnan AN
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():27. PubMed ID: 30187562
    [No Abstract]   [Full Text] [Related]  

  • 5. ACG Clinical Guideline: Management of Crohn's Disease in Adults.
    Lichtenstein GR; Loftus EV; Isaacs KL; Regueiro MD; Gerson LB; Sands BE
    Am J Gastroenterol; 2018 Apr; 113(4):481-517. PubMed ID: 29610508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Esophageal Crohn's disease].
    Gil-Simón P; Barrio J; Saracíbar E; Pérez-Miranda M; Julián L; Antonio Gil Ruiz J; Caro-Patón A
    Gastroenterol Hepatol; 2008 Feb; 31(2):108-9. PubMed ID: 18279653
    [No Abstract]   [Full Text] [Related]  

  • 8. [The value of fecal calprotectin assay in chronic panniculitis of unknown etiology].
    Kaddour K; Lemasson J; Haettich-Pialoux B; Guedj N; Belmatoug N; Treton X; Becheur H; Fantin B; Descamps V; Le Bozec P
    Ann Dermatol Venereol; 2018 Nov; 145(11):702-705. PubMed ID: 30266304
    [No Abstract]   [Full Text] [Related]  

  • 9. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion.
    Rogler G; Aldeguer X; Kruis W; Lasson A; Mittmann U; Nally K; Peyrin-Biroulet L; Schoepfer A; Vatn M; Vavricka S; Logan R
    J Crohns Colitis; 2013 Sep; 7(8):670-7. PubMed ID: 23517932
    [No Abstract]   [Full Text] [Related]  

  • 10. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
    Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
    Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can fecal calprotection identify postoperative recurrence of Crohn's disease?
    Dai C; Jiang M; Sun MJ
    Inflamm Bowel Dis; 2015 May; 21(5):E7. PubMed ID: 25895009
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to can fecal calprotection identify postoperative recurrence of Crohn's disease?
    Qiu Y
    Inflamm Bowel Dis; 2015 May; 21(5):E7. PubMed ID: 25856771
    [No Abstract]   [Full Text] [Related]  

  • 14. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease.
    Pavlidis P; Gulati S; Dubois P; Chung-Faye G; Sherwood R; Bjarnason I; Hayee B
    Scand J Gastroenterol; 2016 Dec; 51(12):1447-1452. PubMed ID: 27400728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Crohn Disease: A Review.
    Cushing K; Higgins PDR
    JAMA; 2021 Jan; 325(1):69-80. PubMed ID: 33399844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor correlation between acute phase reactants and intestinal involvement in patients with onset of Crohn's disease under treatment with an interleukin-6 inhibitor due to seronegative arthropathy.
    Zacarías Martínez L; Mateo Soria L; Mañosa Círia M; Clos Parals A; Cabré Gelada E; Domènech Morral E
    Gastroenterol Hepatol; 2016 Dec; 39(10):670-672. PubMed ID: 26589538
    [No Abstract]   [Full Text] [Related]  

  • 17. What is the role and significance of serum and stool biomarkers in the diagnosis of IBD?
    Palmon R; Brown SJ; Abreu MT
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S187-9. PubMed ID: 18816678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
    Zubin G; Peter L
    Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
    Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The diagnosis of IBD must have a wide foundation].
    Grip O; Halfvarson J; Carlson M; Sternby B
    Lakartidningen; 2009 Nov 4-12; 106(45):2984-6. PubMed ID: 19998823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.